F
Fabien Zoulim
Researcher at French Institute of Health and Medical Research
Publications - 716
Citations - 40988
Fabien Zoulim is an academic researcher from French Institute of Health and Medical Research. The author has contributed to research in topics: Hepatitis B virus & Hepatitis B. The author has an hindex of 96, co-authored 641 publications receiving 35807 citations. Previous affiliations of Fabien Zoulim include Hotel Dieu Hospital & University of Orléans.
Papers
More filters
Journal ArticleDOI
Hepatitis D Virus Infection: Pathophysiology, Epidemiology and Treatment. Report from the first International Delta Cure Meeting 2022
Pietro Lampertico,Elisabetta Degasperi,Lisa Sandmann,Heiner Wedemeyer,Cihan Yurdaydin,Dominique Roulot,Fabien Zoulim,Florin Alexandru Caruntu,Helenie Kefalakes,Julie Lucifora,Kosh Agarwal,Laurent Castera,Maria Buti,Mario Rizzetto,Markus Cornberg,Maura Dandri,Maurizia Rossana Brunetto,Nancy Reau,Robert G. Gish,Saeed Hamid,Soo Aleman,Stephan Urban,Tarik Asselah,Thomas Berg,Victor de Ledinghen +24 more
TL;DR: In this article , a review summarizes key takeaway messages from state-of-the-art lectures as well as research data concerning the hepatitis Delta virus (HDV) field, including the entry inhibitor Bulevirtide and other anti-HBV drugs.
Journal ArticleDOI
Kinetics of hepatitis B core related antigen in patients with compensated HDV cirrhosis treated with Bulevirtide monotherapy for 72 weeks: a single-center study
Elisabetta Degasperi,M. Anolli,D. Sambarino,Floriana Facchetti,Caroline Scholtes,S. U. Uceda Renteria,A. M. Perego,Corinna Orsini,Caroline Charre,Marie-Laure Plissonnier,Ferruccio Ceriotti,S. Monico,Barbara Testoni,Massimo Levrero,Fabien Zoulim,Pietro Lampertico +15 more
Journal ArticleDOI
Modelization, Synthesis and Antiviral Evaluation of New 2,3‐ Disubstituted Thiazolidinone Nucleoside Analogues.
JC Graciet,V. Niddam,M. Gamberoni,C. Trabaud,Jean Dessolin,M. Medou,N. Mourier,Fabien Zoulim,Christelle Borel,Olivier Hantz,Michel Camplo,Jean-Claude Chermann,Jean-Louis Kraus +12 more
Iconography : Hépatite aiguë cytolytique induite par l'imatinib mesylate
Pierre Rocca,Saïd El Jastimi,Jacques Troncy,Jean-Yves Scoazec,Alexandra Boucher,Thierry Vial,Christian Trepo,Fabien Zoulim +7 more
Abstract: L'imatinib mesylate, initialement connu comme le STI 571, commercialise sous le nom de Gleevec® aux Etats Unis et Glivec® en Europe, est un inhibiteur selectif de certains recepteurs tyrosine kinase: la kinase abl intracellulaire, l'oncoproteine de fusion chimerique bcr-abl de la leucemie myeloide chronique, le recepteur c-KIT et le recepteur du PDGF (Platelet-Derived Growth Factor) [1]. L'imatinib mesylate est tres actif chez les malades ayant une leucemie myeloide chronique et d'autres leucemies positives pour le chromosome Philadelphie, dans lesquelles, il inhibe l'activite kinase deregulee de la proteine de fusion bcr-abl [2]. Plus recemment, l'imatinib s'est revele tres efficace dans le traitement des tumeurs stromales gastro-intestinales metastatiques [3]. Nous rapportons un cas d'hepatite aigue liee a la prise de ce medicament chez une malade atteinte de leucemie myeloide chronique.
Journal ArticleDOI
Eliminating cccDNA to cure Hepatitis B virus (HBV) infection.
Fabien Zoulim,Barbara Testoni +1 more
TL;DR: Wang et al. as discussed by the authors proposed a first-in-class orally available HBV cccDNA inhibitor, which can eliminate the persistence of covalently closed circular DNA (cccDNA) in infected hepatocytes.